Funding

AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, ...

The government of UK announced an extra £4.7 billion (US$6.1 billion) into research and development (R&D) by 2020–21, which allayed the fears of many UK scientists which had erupted ahead of Brexit. In this announcement, the biggest winner will be an innovation agency, Innovate UK. Previously known as Technology...

Stada’s €5.3B buyout Sinks, brings in new CEO and CFO After failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft following a board meeting on Tuesday and quickly appoi...

Sanofi investing around $2B into biologics production over next 3 years Following the recent approval of two new biologics, Dupixent and Kevzara, and a pipeline stuffed full of large-molecule drugs, Sanofi will invest as much as €2 billion on its biologics manufacturing network over the next several years. The discl...

The only word that described 2016’s pharma M&A market was “slow.” Some do predict that new year—and administration—could revive energy in the deal making arena, the changes might not happen that fast. The reasons are aplenty, as shares have been sagging under the weight of investor fears of drug-pricing reform. ...